Pharmaceutical Technology Department, National Research Centre, Dokki 12622, Giza, Egypt.
Curr Drug Targets. 2019;20(10):995-1007. doi: 10.2174/1389450120666190307101642.
Medications currently available for the management of diabetes mellitus are inconvenient and have some limitations. Thus, investigations for novel approaches are needed to deliver and target antidiabetics safely to the site of action.
The present review emphasizes the limitations of conventional antidiabetics and provides the recent progresses of nanotechnology in the treatment of diabetes mellitus with a special highlight on the novel nanocarriers methodologies employed as antidiabetic drug delivery systems.
The potential nanocarriers employed for the treatment of diabetes comprise liposomes, niosomes, self-nanoemulsifying drug delivery systems, polymeric nanoparticles, gold nanoparticles, dendrimers and micelles. Herbal nanomedicine has also emerged to be a promising way for adequate delivery of herbal compounds. Other nanotechnology approaches involve the usage of oral insulin, inhalable insulin, artificial pancreas, and nanopump.
Nanocarriers have proved to lead a successful delivery of antidiabetic medications, aiming at drug targeting for enhanced efficacy and safety.
These innovative generations of drug delivery systems have important benefits over conventionally existing ones. The future of nanotechnology in the management of diabetes is still open with several prospects and will be of pronounced significance.
目前用于治疗糖尿病的药物存在使用不便和一些局限性。因此，需要进行新的研究，以安全地将抗糖尿病药物递送到作用部位。
本文重点介绍了传统抗糖尿病药物的局限性，并提供了纳米技术在治疗糖尿病方面的最新进展，特别强调了新型纳米载体方法作为抗糖尿病药物传递系统的应用。
用于治疗糖尿病的潜在纳米载体包括脂质体、非离子型表面活性剂囊泡、自乳化药物传递系统、聚合物纳米粒、金纳米粒、树枝状大分子和胶束。草药纳米医学也已成为充分传递草药化合物的有前途的方法。其他纳米技术方法包括口服胰岛素、吸入性胰岛素、人工胰腺和纳米泵。
纳米载体已被证明可成功递抗糖尿病药物，旨在实现药物靶向以提高疗效和安全性。
这些创新的药物传递系统在各方面均优于传统的药物传递系统。纳米技术在糖尿病管理中的未来仍有许多前景和重要意义。
